Cargando…

Do the Lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline Reduce Systolic Blood Pressure in European Subjects? A Meta-Analysis of Randomized Controlled Trials

BACKGROUND: The milk-derived peptides isoleucine–proline–proline (IPP) and valine–proline– proline (VPP) have been shown to reduce systolic blood pressure (SBP). This decrease is convincingly shown in subjects of Asian origin, but less consistent results have been obtained in European populations. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Cicero, Arrigo F.G., Aubin, Francois, Azais-Braesco, Veronique, Borghi, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565599/
https://www.ncbi.nlm.nih.gov/pubmed/23382495
http://dx.doi.org/10.1093/ajh/hps044
_version_ 1782258463386107904
author Cicero, Arrigo F.G.
Aubin, Francois
Azais-Braesco, Veronique
Borghi, Claudio
author_facet Cicero, Arrigo F.G.
Aubin, Francois
Azais-Braesco, Veronique
Borghi, Claudio
author_sort Cicero, Arrigo F.G.
collection PubMed
description BACKGROUND: The milk-derived peptides isoleucine–proline–proline (IPP) and valine–proline– proline (VPP) have been shown to reduce systolic blood pressure (SBP). This decrease is convincingly shown in subjects of Asian origin, but less consistent results have been obtained in European populations. METHODS: A meta-analysis was conducted in accord with the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) requirements, to assess the effect of IPP and VPP on SBP in Europeans, and to explore some determinants of this effect. RESULTS: Ninety-one publications on the effect of IPP and VPP on SBP in Europeans were identified, and 14 trials with 15 sets of data (n = 1,306) met the inclusion criteria for the meta-analysis. A random-effects model (using the restricted maximum likelihood (REML) estimator) was used for the analysis. Although not all individual trials showed a statistically significant effect of IPP or VPP in reducing SBP, the combination of all data for the two peptides yielded a statistically significantly greater effect for IPP/VPP than for placebo. The decrease in SBP with IPP/VPP was 1.28mm Hg (95% CI, –2.09 to –0.48, P = 0.0017) and the decrease in diastolic BP (DBP) was 0.59mm Hg (95% CI, –1.18 to –0.01, P = 0.047). There was no evidence in the meta-analysis of any publication bias or of heterogeneity (P = 0.13). Among other features, a significant effect was seen for age, with each additional year of age reducing the effect on SBP by 0.09mm Hg. This might be related to isolated systolic hypertension, a condition often encountered in the elderly, who may be poorly responsive to first-line treatments for hypertension. CONCLUSION: The peptides IPP and VPP are effective in moderately reducing SBP in European subjects, as is known for Asian populations. These two peptides could therefore have a role in controlling blood pressure (BP), a prospect that merits their further study.
format Online
Article
Text
id pubmed-3565599
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-35655992014-03-01 Do the Lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline Reduce Systolic Blood Pressure in European Subjects? A Meta-Analysis of Randomized Controlled Trials Cicero, Arrigo F.G. Aubin, Francois Azais-Braesco, Veronique Borghi, Claudio Am J Hypertens Original Article BACKGROUND: The milk-derived peptides isoleucine–proline–proline (IPP) and valine–proline– proline (VPP) have been shown to reduce systolic blood pressure (SBP). This decrease is convincingly shown in subjects of Asian origin, but less consistent results have been obtained in European populations. METHODS: A meta-analysis was conducted in accord with the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) requirements, to assess the effect of IPP and VPP on SBP in Europeans, and to explore some determinants of this effect. RESULTS: Ninety-one publications on the effect of IPP and VPP on SBP in Europeans were identified, and 14 trials with 15 sets of data (n = 1,306) met the inclusion criteria for the meta-analysis. A random-effects model (using the restricted maximum likelihood (REML) estimator) was used for the analysis. Although not all individual trials showed a statistically significant effect of IPP or VPP in reducing SBP, the combination of all data for the two peptides yielded a statistically significantly greater effect for IPP/VPP than for placebo. The decrease in SBP with IPP/VPP was 1.28mm Hg (95% CI, –2.09 to –0.48, P = 0.0017) and the decrease in diastolic BP (DBP) was 0.59mm Hg (95% CI, –1.18 to –0.01, P = 0.047). There was no evidence in the meta-analysis of any publication bias or of heterogeneity (P = 0.13). Among other features, a significant effect was seen for age, with each additional year of age reducing the effect on SBP by 0.09mm Hg. This might be related to isolated systolic hypertension, a condition often encountered in the elderly, who may be poorly responsive to first-line treatments for hypertension. CONCLUSION: The peptides IPP and VPP are effective in moderately reducing SBP in European subjects, as is known for Asian populations. These two peptides could therefore have a role in controlling blood pressure (BP), a prospect that merits their further study. Oxford University Press 2013-03 2013-01-07 /pmc/articles/PMC3565599/ /pubmed/23382495 http://dx.doi.org/10.1093/ajh/hps044 Text en © The Author 2013. Published by Oxford University Press on behalf of the American Journal of Hypertension. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Cicero, Arrigo F.G.
Aubin, Francois
Azais-Braesco, Veronique
Borghi, Claudio
Do the Lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline Reduce Systolic Blood Pressure in European Subjects? A Meta-Analysis of Randomized Controlled Trials
title Do the Lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline Reduce Systolic Blood Pressure in European Subjects? A Meta-Analysis of Randomized Controlled Trials
title_full Do the Lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline Reduce Systolic Blood Pressure in European Subjects? A Meta-Analysis of Randomized Controlled Trials
title_fullStr Do the Lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline Reduce Systolic Blood Pressure in European Subjects? A Meta-Analysis of Randomized Controlled Trials
title_full_unstemmed Do the Lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline Reduce Systolic Blood Pressure in European Subjects? A Meta-Analysis of Randomized Controlled Trials
title_short Do the Lactotripeptides Isoleucine–Proline–Proline and Valine–Proline–Proline Reduce Systolic Blood Pressure in European Subjects? A Meta-Analysis of Randomized Controlled Trials
title_sort do the lactotripeptides isoleucine–proline–proline and valine–proline–proline reduce systolic blood pressure in european subjects? a meta-analysis of randomized controlled trials
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565599/
https://www.ncbi.nlm.nih.gov/pubmed/23382495
http://dx.doi.org/10.1093/ajh/hps044
work_keys_str_mv AT ciceroarrigofg dothelactotripeptidesisoleucineprolineprolineandvalineprolineprolinereducesystolicbloodpressureineuropeansubjectsametaanalysisofrandomizedcontrolledtrials
AT aubinfrancois dothelactotripeptidesisoleucineprolineprolineandvalineprolineprolinereducesystolicbloodpressureineuropeansubjectsametaanalysisofrandomizedcontrolledtrials
AT azaisbraescoveronique dothelactotripeptidesisoleucineprolineprolineandvalineprolineprolinereducesystolicbloodpressureineuropeansubjectsametaanalysisofrandomizedcontrolledtrials
AT borghiclaudio dothelactotripeptidesisoleucineprolineprolineandvalineprolineprolinereducesystolicbloodpressureineuropeansubjectsametaanalysisofrandomizedcontrolledtrials